Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Insulin Glargine Provides Greater Improvements In Glycaemic Control Vs. Intensifying Lifestyle Management For People With Type 2 Diabetes Treated With OADs And 7–8% A1c Levels. The TULIP Study

J. Blicklé, N. Hancu, M. Piletič, V. Profozič, M. Shestakova, M-P Dain, S. Jacqueminet, A. Grimaldi
Published 2009 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Aim:  To determine whether earlier administration of insulin glargine (glargine) vs. the intensification of lifestyle management (LM) improves glycaemic control in type 2 diabetes patients with A1c 7–8% treated with oral therapy.
This paper references
10.2337/DIACARE.27.7.1535
The burden of treatment failure in type 2 diabetes.
J. Brown (2004)
10.1007/s00125-006-0316-2
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy
D. Nathan (2006)
10.2337/DIACARE.28.2.254
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
H. Janka (2005)
OA j Insulin glargine vs. lifestyle management
10.1111/j.1464-5491.2004.01285a.x
A review of basal insulins
E. Chantelau (2004)
Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial
RJ Sigal (2007)
National diabetes fact sheet , United States , 2005
M Peyrot
The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study
HU Janka (2006)
10.1093/CLINCHEM/45.8.1339
Type 2 diabetes: an overview.
H. Lebovitz (1999)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
R. Turner (1998)
10.1186/1477-7525-5-57
The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ
C. Bradley (2007)
10.1056/NEJMoa0802743
Effects of intensive glucose lowering in type 2 diabetes.
H. Gerstein (2008)
10.1016/S1098-3597(07)80018-4
The benefits of tight glycemic control in type 2 diabetes mellitus.
D. Leroith (2007)
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES
H. C. Gerstein (2010)
10.2337/DIACARE.28.10.2543
Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.
W. Polonsky (2005)
10.2337/dc06-0805
Standards of Medical Care in Diabetes–2006
Kingston H. Tseng (2006)
Insulin Glargine 4002 Study Investigators: the treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
M Riddle (2003)
10.1007/s00125-005-0132-0
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study
H. Yki–Järvinen (2005)
10.1016/S0140-6736(08)60485-7
Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial
R. Bretzel (2008)
10.1016/S0084-3741(09)79280-7
Effects of Intensive Glucose Lowering in Type 2 Diabetes
S. Schinner (2009)
10.1016/J.CLINTHERA.2007.07.005
Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
A. Vinik (2007)
10.1016/J.DIABRES.2007.03.021
Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study.
R. Houlden (2007)
10.2337/DIACARE.29.04.06.DC05-0053
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
M. Peyrot (2005)
10.2337/DIACARE.26.11.3080
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
M. Riddle (2003)
10.1016/S0084-3741(08)70283-X
Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes
J. Leahy (2006)



This paper is referenced by
10.1016/s1957-2557(11)70330-3
Diabète de type 2 après échec de multithérapie orale : critères décisionnels personnalisés pour l’intensification du traitement
B. Guerci (2011)
10.1016/j.diabet.2016.11.007
Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options.
D. Raccah (2017)
10.1007/s13300-018-0371-y
Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
C. Neslusan (2018)
10.35537/10915/39028
Metabolismo de lípidos y disfunción endotelial en pacientes diabéticos tipo 2 tratados con insulina o hipoglucemiantes orales
Fernando Ariel Marra (2014)
10.4158/EP13075.OR
Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus.
S. Garg (2014)
When to Start Insulin Treatment for Type 2 Diabetes Patients ?
D. W. Chan ()
Early Insulin Glargine Initiation in Iranian People With Uncontrolled Type 2 Diabetes: Glycemic Control, and Adverse Events
M. Khamseh (2018)
10.3810/pgm.2014.05.2766
Efficacy and Risk of Hypoglycemia With Use of Insulin Glargine or Comparators in Patients With Cardiovascular Risk Factors
L. Blonde (2014)
Biomarcadores emergentes para diferentes patologías humanas* Emerging biomarkers for different human pathologies Biomarcadores emergentes para diferentes doenças humanas
C. Marra (2013)
10.1089/dia.2009.0127
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
S. Garg (2010)
10.1016/j.jdiacomp.2014.09.012
Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA)
M. Odawara (2015)
10.4236/JDM.2014.43033
Treatment Satisfaction with Insulin Glargine in Insulin-Naïve Type 2 Diabetes Patients—A Hong Kong Based Registry
W. Chan (2014)
10.14341/PROBL201258356-60
The importance and advantages of the timely prescription of insulin to the patients with type 2 diabetes mellitus
I R Iarek-Martynova (2012)
10.14341/PROBL201258361-64
Modern approaches to the treatment of type 2 diabetes mellitus and its complications
A. Ametov (2012)
10.1089/dia.2010.0250
Combining basal insulin analogs with glucagon-like peptide-1 mimetics.
R. Perfetti (2011)
10.1016/j.jdiacomp.2011.03.005
Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review.
D. Giugliano (2011)
10.1111/j.1463-1326.2009.01060.x
Patient‐directed titration for achieving glycaemic goals using a once‐daily basal insulin analogue: an assessment of two different fasting plasma glucose targets ‐ the TITRATETM study
L. Blonde (2009)
10.1089/met.2010.0134
Insulin analogs and glycosylated hemoglobin target of less than 7% in type 2 diabetes: a systematic review of randomized trials.
K. Esposito (2011)
UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS MÉDICAS: ENDOCRINOLOGIA
Alberto Luiz Gil (2007)
10.7707/hmj.441
Initiation of insulin glargine plus oral antidiabetic drugs in patients with type 2 diabetes uncontrolled on premixed insulin
G. Kaddaha (2017)
10.1016/j.endonu.2014.06.004
Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia.
S. Azriel (2014)
10.1530/EJE-11-0022
THERAPY OF ENDOCRINE DISEASE: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues
A. Vaag (2012)
10.1016/j.diabres.2013.10.001
Effect of gender on treatment outcomes in type 2 diabetes mellitus.
J. McGill (2013)
10.3111/13696998.2011.605818
Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID
O. Başer (2011)
10.1371/journal.pone.0087799
Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
C. Park (2014)
10.1007/s40266-013-0069-9
Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes
Naushira Pandya (2013)
10.1016/J.ENDOEN.2014.11.004
Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia
S. Azriel (2014)
10.3810/pgm.2014.05.2761
Influence of Baseline Glycemia on Outcomes With Insulin Glargine Use in Patients Uncontrolled on Oral Agents
M. Banerji (2014)
L'insulinothérapie chez les diabétiques de type deux
Esma Benammar (2009)
10.1111/ijcp.12747
How much is too much? Outcomes in patients using high‐dose insulin glargine
T. Reid (2016)
10.1111/j.1463-1326.2011.01523.x
The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
A. Barnett (2012)
10.7326/0003-4819-154-10-201105170-00007
Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis
J. Gross (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar